A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.

ABSTRACT:

SUBMITTER: Reddy NM 

PROVIDER: S-EPMC5214342 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature